Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network.

MLA

Massicotte, Marie-Hélène, et al. “Tyrosine Kinase Inhibitor Treatments in Patients with Metastatic Thyroid Carcinomas: A Retrospective Study of the TUTHYREF Network.” European Journal of Endocrinology, vol. 170, no. 4, Mar. 2014, pp. 575–82. EBSCOhost, https://doi.org/10.1530/EJE-13-0825.

APA

Massicotte, M.-H., Brassard, M., Claude-Desroches, M., Borget, I., Bonichon, F., Giraudet, A.-L., Do Cao, C., Chougnet, C. N., Leboulleux, S., Baudin, E., Schlumberger, M., & de la Fouchardière, C. (2014). Tyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF network. European Journal of Endocrinology, 170(4), 575–582. https://doi.org/10.1530/EJE-13-0825

Chicago

Massicotte, Marie-Hélène, Maryse Brassard, Médéric Claude-Desroches, Isabelle Borget, Françoise Bonichon, Anne-Laure Giraudet, Christine Do Cao, et al. 2014. “Tyrosine Kinase Inhibitor Treatments in Patients with Metastatic Thyroid Carcinomas: A Retrospective Study of the TUTHYREF Network.” European Journal of Endocrinology 170 (4): 575–82. doi:10.1530/EJE-13-0825.